表紙
市場調查報告書

幹細胞治療藥的受託製造市場:2019-2030年

Stem Cell Therapy Contract Manufacturing Market, 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 911897
出版日期 內容資訊 英文 320 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
幹細胞治療藥的受託製造市場:2019-2030年 Stem Cell Therapy Contract Manufacturing Market, 2019-2030
出版日期: 2019年08月31日內容資訊: 英文 320 Pages
簡介

本報告提供幹細胞治療藥的開發、製造介入的受託服務供應商的相關調查,各種幹細胞治療藥CMO (醫藥品受託製造廠商)的製造能力的分析,市場概要,法規環境,各地區的主要企業的簡介,機會的評估,需求分析,及市場預測等彙整資料。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 幹細胞治療藥
  • 幹細胞治療藥的供應鏈
  • 幹細胞治療藥的製造

第4章 市場概要

  • 本章概要
  • 幹細胞治療藥的CMO:市場參與企業的清單
  • 幹細胞治療藥的CMO:非市場參與企業的清單
  • 幹細胞治療藥:裡面制廠商

第5章 法規形勢

  • 本章概要
  • 目前方案
  • 細胞療法藥的製造的認證評估
  • 體細胞來源治療藥的指南
  • 現有的課題

第6章 北美幹細胞治療藥的受託製造商

  • 本章概要
  • FUJIFILM Cellular Dynamics
  • GenCure
  • Progenitor Cell Therapy (PCT)
  • Waisman Biomanufacturing
  • WuXi Advanced Therapeutics

第7章 歐洲、亞太地區的幹細胞治療藥的受託製造商

  • 本章概要
  • 歐洲的主要企業
    • BioNTech Innovative Manufacturing Services
    • Cell and Gene Therapy Catapult
    • Lonza
    • Roslin Cells
  • 亞太地區的主要企業
    • MEDINET
    • Nikon CeLL innovation

第8章 聯盟、合作

  • 本章概要
  • 聯盟模式
  • 聯盟、合作的清單

第9章 受託製造的機會評估

  • 本章概要
  • 幹細胞治療藥及開發者
  • 北美幹細胞治療藥的CMO
  • 歐洲的幹細胞治療藥的CMO
  • 亞太地區的幹細胞治療藥的CMO

第10章 製造能力分析

  • 本章概要
  • 前提條件、調查手法
  • 全球製造能力 (市場參與企業) :無塵室數
  • 全球製造能力 (市場參與企業) :無塵室的區域
  • 全球製造能力 (非市場參與企業) :無塵室數
  • 全球製造能力 (非市場參與企業) :無塵室數
  • 彙整

第11章 需求分析

  • 本章概要
  • 前提條件、調查手法
  • 全球幹細胞治療藥製造臨床需求
  • 全球幹細胞治療藥製造的商業需求
  • 供需分析
  • 結論

第12章 市場預測

  • 本章概要
  • 預測手法、主要的前提條件
  • 整體幹細胞治療藥的受託製造市場
  • 流通預測:幹細胞的各類型
  • 流通預測:幹細胞的各來源
  • 流通預測:各營運規模
  • 流通預測:各企業規模
  • 流通預測:各地區

第13章 KPI (重要業績指標)

  • 本章概要
  • 幹細胞治療藥的受託製造商:KPI

第14章 彙整

第15章 執行見解

  • 本章概要
  • Bio Elpida
  • Roslin Cell Therapies
  • University of Minnesota
  • Waisman Biomanufacturing
  • Yposkesi

第16章 附錄1:總計資料

第17章 附錄2:分析對象企業、組織的一覽

目錄

Example Insights:

Overview:

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs) . Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

Scope of the Report:

The “Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030” report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs. Amongst other elements, the report includes:

  • A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology).
  • An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions.
  • Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook.
  • An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership.
  • An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
  • A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies.
  • An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota
  • Fiona Bellot, Business Development Manager, Roslin Cell Therapies
  • Gilles Devillers, General Manager, Bio Elpida
  • Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the stem cell therapy contract manufacturing market in the mid to long term.

Chapter 3 provides a brief introduction to the basic concepts related to stem cell therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the disease indications targeted by such interventions. It also includes a discussion on the different manufacturing models (centralized and decentralized) that are used for the production of stem cell therapies, along with a list of advantages and disadvantages. Further, it provides details on the scalability of stem cell therapies. The chapter also includes a brief overview on the role of automation and supply chain management, with respect to stem cell therapies.

Chapter 4 provides a comprehensive overview of the global stem cell therapy contract manufacturing landscape. It includes information related to over 80 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogeneic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). In addition, the chapter presents a list of the in-house players involved in manufacturing of stem cell therapies.

Chapter 5 provides a detailed description on the regulatory landscape related to stem cells and cell therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Further, it presents an analysis of the manufacturing facilities on the basis of certifications awarded (for contract manufacturing stem cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 7 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in emerging regions such as Europe and Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 8 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2015. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreement, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 presents a detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. The chapter presents a list of stem cell therapies along with other details, such as stage of development, source of stem cell therapy and location of the developer.

Chapter 10 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of stem cell therapy products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, and large CMOs) in the market, using data from both secondary and primary research. The results of this analysis were used to establish an informed opinion on the stem cell therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small-sized, mid-sized and large-sized organizations).

Chapter 11 features an illustrative view on the demand for stem cell therapies (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of stem cell therapy manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of stem cell therapies that have been registered since 2010. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, leading industry / non-industry sponsors, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the commercialized stem cell products, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world).

Chapter 13 features an analysis on the key performance indicators of service providers based on the information available for top-ten (based on the annual revenues generated in 2017)

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion on the stem cell therapies contract manufacturing market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of stem cell therapy contract manufacturing market.

Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy contract manufacturing domain. We have inputs from Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), Gilles Devillers (General Manager, Bio Elpida) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Stem Cell Therapies
    • 3.2.1. Classification of Stem Cells
      • 3.2.1.1. Based on Stem Cell Potency
      • 3.2.1.2. Based on Stem Cell Origin
      • 3.2.1.3. Based on Stem Cell Source
    • 3.2.2. Application of Stem Cell Therapies
    • 3.2.3. Administration of Stem Cell Therapies
    • 3.2.4. Commercialized Stem Cell Therapies
  • 3.3. Stem Cell Therapy Supply Chain
    • 3.3.1. Donor Eligibility and Selection
    • 3.3.2. Manufacturing
    • 3.3.3. Logistics
    • 3.3.4. Patient Verification and Treatment
    • 3.3.5. Sample Collection
    • 3.3.6. Growth Drivers and Roadblocks
    • 3.3.7. Future Perspectives
  • 3.4. Stem Cell Therapy Manufacturing
    • 3.4.1. Types of Manufacturing Models
      • 3.4.1.1. Centralized Manufacturing Model
      • 3.4.1.2. Decentralized Manufacturing Model
    • 3.4.2. Scalability of the Stem Cell Manufacturing Process
      • 3.4.2.1. Scale-Up
      • 3.4.2.2. Scale-Out
    • 3.4.3. Important Factors for Stem Cell Therapy Manufacturing
      • 3.4.3.1. Characterization
      • 3.4.3.2. Cost of Goods
    • 3.4.4. Automation of Stem Cell Therapy Manufacturing
    • 3.4.5. Stem Cell Therapy Contract Manufacturing
      • 3.4.5.1. Need for Outsourcing
      • 3.4.5.2. Advantages of Outsourcing Manufacturing Operations
      • 3.4.5.3. Basic Guidelines for Selecting a CMO Partner
    • 3.4.6. Key Challenges and Drivers of the Stem Cell Contract Manufacturing Market

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Stem Cell Therapy CMOs: List of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Manufacturing Facilities
    • 4.2.5. Analysis by Types of Services Offered
    • 4.2.6. Analysis by Scale of Operation
    • 4.2.7. Analysis by Types of Stem Cells
    • 4.2.8. Analysis by Source of Stem Cells
    • 4.2.9. Analysis by Therapeutic Area
  • 4.3. Stem Cell Therapy CMOs: List of Non-Industry Players
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Location of Headquarters
    • 4.3.3. Analysis by Location of Manufacturing Facilities
    • 4.3.4. Analysis by Types of Services Offered
    • 4.3.5. Analysis by Scale of Operation
    • 4.3.6. Analysis by Types of Stem Cells
    • 4.3.7. Analysis by Source of Stem Cells
    • 4.3.8. Analysis by Therapeutic Area
  • 4.4. Stem Cell Therapies: In-House Manufacturers

5. REGULATORY LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Current Scenario
    • 5.2.1. Regulatory System in the North America
    • 5.2.2. Regulatory System in Europe
    • 5.2.3. Regulatory System in Japan
    • 5.2.4. Conditional Approvals
  • 5.3. Accreditations for Cell Therapy Manufacturing
    • 5.3.1. Information on Facility Approvals Granted by Various Regulatory Authorities
  • 5.4. Guidelines for Manufacturing Cell-based Therapies
  • 5.5. Existing Challenges
    • 5.5.1. Variability in Regulatory Guidelines across Different Geographies

6. STEM CELL THERAPY CONTRACT MANUFACTURERS IN NORTH AMERICA

  • 6.1. Chapter Overview
  • 6.2. FUJIFILM Cellular Dynamics
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Manufacturing Capabilities and Facilities
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. GenCure
    • 6.3.1. Company Overview
    • 6.3.2. Manufacturing Capabilities and Facilities
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Progenitor Cell Therapy (PCT)
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Manufacturing Capabilities and Facilities
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Waisman Biomanufacturing
    • 6.5.1. Company Overview
    • 6.5.2. Manufacturing Capabilities and Facilities
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. WuXi Advanced Therapeutics
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Manufacturing Capabilities and Facilities
    • 6.6.4. Recent Developments and Future Outlook

7. STEM CELL THERAPY CONTRACT MANUFACTURERS IN EUROPE AND ASIA-PACIFIC

  • 7.1. Chapter Overview
  • 7.2. Key Players in Europe
    • 7.2.1. BioNTech Innovative Manufacturing Services
      • 7.2.1.1. Company Overview
      • 7.2.1.2. Manufacturing Capabilities and Facilities
      • 7.2.1.3. Recent Developments and Future Outlook
    • 7.2.2. Cell and Gene Therapy Catapult
      • 7.2.2.1. Company Overview
      • 7.2.2.2. Manufacturing Capabilities and Facilities
      • 7.2.2.3. Recent Developments and Future Outlook
    • 7.2.3. Lonza
      • 7.2.3.1. Company Overview
      • 7.2.3.2. Financial Information
      • 7.2.3.3. Manufacturing Capabilities and Facilities
      • 7.2.3.4. Recent Developments and Future Outlook
    • 7.2.4. Roslin Cells
      • 7.2.4.1. Company Overview
      • 7.2.4.2. Manufacturing Capabilities and Facilities
      • 7.2.4.3. Recent Developments and Future Outlook
  • 7.3. Key Players in Asia Pacific
    • 7.3.1. MEDINET
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Manufacturing Capabilities and Facilities
      • 7.3.1.3. Recent Developments and Future Outlook
    • 7.3.2. Nikon CeLL innovation
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Information
      • 7.3.2.3. Manufacturing Capabilities and Facilities
      • 7.3.2.4. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATION

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Stem Cell Therapy Contract Manufacturing: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Types of Stem Cells
    • 8.3.4. Analysis by Scale of Operation
    • 8.3.5. Most Active Players: Analysis by Number of Partnerships
    • 8.3.6. Regional Analysis
  • 8.3.6.1. Intercontinental and Intracontinental Agreements

9. CONTRACT MANUFACTURING OPPORTUNITY ASSESSMENT

  • 9.1. Chapter Overview
  • 9.2. Stem Cell Therapies and Developers
  • 9.3. Stem Cell Therapy CMOs in North America
    • 9.3.1. Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
    • 9.3.2. Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
    • 9.3.3. Contract Manufacturing Opportunity Assessment for Commercialized Molecules
  • 9.4. Stem Cell Therapy CMOs in Europe
    • 9.4.1. Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
    • 9.4.2. Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
    • 9.4.3. Contract Manufacturing Opportunity Assessment for Commercialized Molecules
  • 9.5. Stem Cell Therapy CMOs in Asia Pacific
    • 9.5.1. Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
    • 9.5.2. Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
    • 9.5.3. Contract Manufacturing Opportunity Assessment for Commercialized Molecules

10. CAPACITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Methodology
  • 10.3. Stem Cell Contract Manufacturing Market (Industry Players): Global Production Capacity in Terms of Number of Clean Rooms
    • 10.3.1. Analysis by Company Size
    • 10.3.2. Analysis by Scale of Operation
    • 10.3.3. Analysis by Geographical Region
  • 10.4. Stem Cell Contract Manufacturing Market (Industry Players): Global Production Capacity in Terms of Area of Clean Rooms
    • 10.4.1. Analysis by Company Size
    • 10.4.2. Analysis by Scale of Operation
    • 10.4.3. Analysis by Geographical Region
  • 10.5. Stem Cell Therapy Contract Manufacturing (Non-Industry Players): Global Production Capacity in Terms of Number of Clean Rooms
    • 10.5.1. Analysis by Scale of Operation
    • 10.5.2. Analysis by Geographical Region
  • 10.6. Stem Cell Therapy Contract Manufacturing (Non-Industry Players): Global Production Capacity in Terms of Area of Clean Rooms
    • 10.6.1. Analysis by Scale of Operation
    • 10.6.2. Analysis by Geographical Region
  • 10.7. Concluding Remarks

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Global Clinical Demand for Stem Cell Therapy Manufacturing
    • 11.3.1. Analysis by Types of Stem Cells
    • 11.3.2. Analysis by Source of Stem Cells
    • 11.3.3. Analysis by Geographical Location
  • 11.4. Global Commercial Demand for Stem Cell Therapy Manufacturing
    • 11.4.1. Analysis by Types of Stem Cells
    • 11.4.2. Analysis by Source of Stem Cells
    • 11.4.3. Analysis by Geographical Location
  • 11.5. Demand and Supply Analysis
  • 11.6. Conclusion

12. MARKET FORECAST

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Overall Stem Cell Therapy Contract Manufacturing Market, 2019-2030
  • 12.4. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells
  • 12.5. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells
  • 12.6. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
  • 12.7. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size
  • 12.8. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography
    • 12.8.1. Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030
      • 12.8.1.1. Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030
      • 12.8.1.2. Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030
      • 12.8.1.3. Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030
      • 12.8.1.4. Stem Cell Therapy Contract Manufacturing Market in North America for Allogeneic Stem Cell Therapies, 2019-2030
      • 12.8.1.5. Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Therapies Stem Cells, 2019-2030
      • 12.8.1.6. Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030
      • 12.8.1.7. Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030
      • 12.8.1.8. Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030
      • 12.8.1.9. Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030
      • 12.8.1.10. Stem Cell Therapy Contract Manufacturing Market in North America for Large Companies, 2019-2030
    • 12.8.2. Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030
      • 12.8.2.1. Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030
      • 12.8.2.2. Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030
      • 12.8.2.3. Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030
      • 12.8.2.4. Stem Cell Therapy Contract Manufacturing Market in Europe for Allogeneic Stem Cell Therapies, 2019-2030
      • 12.8.2.5. Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030
      • 12.8.2.6. Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030
      • 12.8.2.7. Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030
      • 12.8.2.8. Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030
      • 12.8.2.9. Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030
      • 12.8.2.10. Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030
    • 12.8.3. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, 2019-2030
      • 12.8.3.1. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Adult Stem Cell-based Therapies, 2019-2030
      • 12.8.3.2. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Embryonic Stem Cell-based Therapies, 2019-2030
      • 12.8.3.3. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030
      • 12.8.3.4. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Allogeneic Stem Cell Therapies, 2019-2030
      • 12.8.3.5. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Autologous Stem Cell Therapies, 2019-2030
      • 12.8.3.6. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Operations, 2019-2030
      • 12.8.3.7. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Commercial Operations, 2019-2030
      • 12.8.3.8. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030
      • 12.8.3.9. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030
      • 12.8.3.10. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030

13. KEY PERFORMANCE INDICATORS

  • 13.1. Chapter Overview
  • 13.2. Stem Cell Therapy Contract Manufacturers: Key Performance Indicators
    • 13.2.1. Financial Indicators
      • 13.2.1.1. Big Pharma Perspective
      • 13.2.1.2. Contract Manufacturers' Perspective
    • 13.2.2. Process and Capability Indicators
      • 13.2.2.1. Big Pharma Perspective
      • 13.2.2.2. Contract Manufacturers' Perspective
    • 13.2.3. Market Reputation Indicators
      • 13.2.3.1. Big Pharma Perspective
      • 13.2.3.2. Contract Manufacturers' Perspective
  • 13.3. Conclusion

14. CONCLUDING REMARK

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Bio Elpida
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Gilles Devillers, General Manager
  • 15.3. Roslin Cell Therapies
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Fiona Bellot, Business Development Manager
  • 15.4. University of Minnesota
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine
  • 15.5. Waisman Biomanufacturing
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Brian Dattilo, Manager of Business Development
  • 15.6. Yposkesi
    • 15.6.1. Company Snapshot
    • 15.6.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Evolution of Stem Cell Research
  • Figure 3.2. Classification of Stem Cells
  • Figure 3.3. Potential Application Areas for Stem Cell Therapies
  • Figure 3.4. Key Processes in the Stem Cell Therapies Supply Chain
  • Figure 3.5. Key Steps Involved in Manufacturing Stem Cell Therapies
  • Figure 3.6. Keys Steps Involved in Logistics Operations of Autologous Therapies
  • Figure 3.7. Stem cell Therapy supply Chain Solutions: Growth Drivers and Roadblocks
  • Figure 3.8. Centralized Manufacturing: Process Model
  • Figure 3.9. Decentralized Manufacturing: Process Model
  • Figure 3.10. Types of Contract Manufacturers
  • Figure 3.11. Key Factors to Consider while Selecting a CMO Partner
  • Figure 3.12. Stem Cell Therapy: Challenges and Drivers
  • Figure 4.1. Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
  • Figure 4.2. Stem Cell Therapy CMOs (Industry): Distribution by Company Size
  • Figure 4.3. Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
  • Figure 4.5. Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facility
  • Figure 4.6. Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
  • Figure 4.7. Stem Cell Therapy CMOs (Industry): Distribution by Scale of Operation
  • Figure 4.8. Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cells
  • Figure 4.9. Stem Cell Therapy CMOs (Industry): Distribution by Types of Stem Cells
  • Figure 4.10. Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
  • Figure 4.11. Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters
  • Figure 4.12. Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Manufacturing Facility
  • Figure 4.13. Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Services Offered
  • Figure 4.14. Stem Cell Therapy CMOs: Distribution by Scale of Operation
  • Figure 4.15. Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cells
  • Figure 4.16. Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Stem Cells
  • Figure 5.1. Stem Cell CMOs: Distribution of Manufacturing Facilities by Regulatory Authorities
  • Figure 6.1. FUJIFILM Cellular Dynamics: Annual Revenues, 2014- Q1 2019 (USD Million)
  • Figure 6.2. Hitachi: Annual Revenues, 2015- Q1 2019 (YEN Billion)
  • Figure 6.3. WuXi Advanced Therapies: Annual Revenues, 2015- 2018 (RMB Million)
  • Figure 7.1. Lonza: Annual Revenues, 2012- 2018 (CHF Million)
  • Figure 7.2. Nikon CeLL innovation: Annual Revenues, 2015- 2018 (YEN Million)
  • Figure 8.1. Partnerships and Collaborations: Cumulative Trend by Year, 2015-2019
  • Figure 8.2. Partnerships and Collaborations: Distribution by Type of Agreement
  • Figure 8.3. Partnerships and Collaborations: Trend by Type of Agreement and Year (2015-2019)
  • Figure 8.4. Partnerships and Collaborations: Distribution by Types of Stem Cells
  • Figure 8.5. Partnerships and Collaborations: Distribution by Scale of Operation and Type of Agreement
  • Figure 8.6. Most Active Players: Analysis by Number of Partnerships
  • Figure 8.7. Partnerships and Collaborations: Regional Distribution
  • Figure 8.9. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 9.1. Stem Cell Therapy CMOs in North America: Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
  • Figure 9.2. Stem Cell Therapy CMOs in North America: Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
  • Figure 9.3. Stem Cell Therapy CMOs in North America: Contract Manufacturing Opportunity Assessment for Commercial Stage Molecules
  • Figure 9.4. Stem Cell Therapy CMOs in Europe: Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
  • Figure 9.5. Stem Cell Therapy CMOs in Europe: Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
  • Figure 9.6. Stem Cell Therapy CMOs in Europe: Contract Manufacturing Opportunity Assessment for Commercial Stage Molecules
  • Figure 9.7. Stem Cell Therapy CMOs in Asia Pacific: Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
  • Figure 9.8. Stem Cell Therapy CMOs in Asia Pacific: Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
  • Figure 9.9. Stem Cell Therapy CMOs in Asia Pacific: Contract Manufacturing Opportunity Assessment for Commercial Stage Molecules
  • Figure 10.1. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
  • Figure 10.2. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
  • Figure 10.3. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
  • Figure 10.4. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
  • Figure 10.5. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 10.6. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Range of Installed Capacity
  • Figure 10.7. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
  • Figure 10.8. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
  • Figure 10.9. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 10.10. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
  • Figure 10.11. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
  • Figure 10.12. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
  • Figure 10.13. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 10.14. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Range of Installed Capacity
  • Figure 10.15. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
  • Figure 10.16. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 11.1. Global Clinical Demand for Stem Cell Therapies
  • Figure 11.2. Clinical Demand for Stem Cell Therapies: Distribution by Types of Stem Cells
  • Figure 11.3. Clinical Demand for Stem Cell Therapies: Distribution by Source of Stem Cells
  • Figure 11.4. Clinical Demand for Stem Cell Therapies: Distribution by Geographical Location
  • Figure 11.5. Global Commercial Demand for Stem Cell Therapies
  • Figure 11.6. Commercial Demand for Stem Cell Therapies: Distribution by Types of Stem Cells
  • Figure 11.7. Commercial Demand for Stem Cell Therapies: Distribution by Source of Stem Cells
  • Figure 11.8. Commercial Demand for Stem Cell Therapies: Distribution by Geographical Location
  • Figure 11.9. Demand and Supply Distribution
  • Figure 12.1. Overall Stem Cell Therapy Contract Manufacturing Market, 2019-2030 (USD Million)
  • Figure 12.2. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells (USD Million)
  • Figure 12.3. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells (USD Million)
  • Figure 12.4. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
  • Figure 12.5. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size (USD Million)
  • Figure 12.6. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
  • Figure 12.7. Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030 (USD Million)
  • Figure 12.8. Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.9. Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.10. Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.11. Stem Cell Therapy Contract Manufacturing Market in North America for Allogeneic Stem Cell Therapies, 2019-2030 (USD Million)
  • Figure 12.12. Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
  • Figure 12.13. Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
  • Figure 12.14. Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
  • Figure 12.15. Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
  • Figure 12.16. Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
  • Figure 12.17. Stem Cell Therapy Contract Manufacturing Market in North America For Large Companies, 2019-2030 (USD Million)
  • Figure 12.18. Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
  • Figure 12.19. Stem Cell Therapy Contract Manufacturing Market in Italy, 2019-2030 (USD Million)
  • Figure 12.20. Stem Cell Therapy Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
  • Figure 12.21. Stem Cell Therapy Contract Manufacturing Market in France, 2019-2030 (USD Million)
  • Figure 12.22. Stem Cell Therapy Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
  • Figure 12.23. Stem Cell Therapy Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
  • Figure 12.24. Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.25. Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.26. Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.27. Stem Cell Therapy Contract Manufacturing Market in Europe for Allogeneic Stem Cell Therapies, 2019-2030 (USD Million)
  • Figure 12.28. Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
  • Figure 12.29. Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
  • Figure 12.30. Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
  • Figure 12.31. Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
  • Figure 12.32. Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
  • Figure 12.33. Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030 (USD Million)
  • Figure 12.34. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World, 2019-2030 (USD Million)
  • Figure 12.35. Stem Cell Therapy Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
  • Figure 12.36. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.37. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.38. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Figure 12.39. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
  • Figure 12.40. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
  • Figure 13.1. Stem Cell Therapy Contract Manufacturers: Key Performance Indicators (KPIs)
  • Figure 13.2. Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
  • Figure 13.3. Financial Indicators: Big Pharma Perspective
  • Figure 13.4. Financial Indicators: Contract Manufacturers' Perspective
  • Figure 13.5. Process / Capability Indicators: Comparative Analysis of KPIs of Big Pharma Companies
  • Figure 13.6. Process / Capability Indicators: Big Pharma Perspective
  • Figure 13.7. Process / Capability Indicators: Contract Manufacturers' Perspective
  • Figure 13.8. Market Reputation Indicators: Comparative Analysis of KPIs of Big Pharma Companies
  • Figure 13.9. Market Reputation Indicators: Big Pharma Perspective
  • Figure 13.10. Market Reputation Indicators: Contract Manufacturers' Perspective

List of Tables

  • Table 3.1. Differences between Stem Cell Therapies and Other Biotechnology Products
  • Table 3.2. Approved Stem Cell Therapies
  • Table 3.3. Assessment Strategies for Different Manufacturing Processes
  • Table 3.4. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 4.1. Stem Cell Therapy Contract Manufacturers: List of Industry Players
  • Table 4.2. Stem Cell Therapy CMOs: Information on Type of Services Offered (Industry Players)
  • Table 4.3. Stem Cell Therapy CMOs: Information on Scale of Operation (Industry Players)
  • Table 4.4. Stem Cell Therapy CMOs: Information on Type and Source of Stem Cells (Industry Players)
  • Table 4.5. Stem Cell Therapy Contract Manufacturers: List of Non-Industry Players
  • Table 4.6. Stem Cell Therapy CMOs: Information on Type of Services Offered (Non-Industry Players)
  • Table 4.7. Stem Cell Therapy CMOs: Information on Scale of Operation (Non-Industry Players)
  • Table 4.8. Stem Cell Therapy CMOs: Information on Source of Stem Cells (Non-Industry Players)
  • Table 4.9. Stem Cell Therapy CMOs: Information on Type of Stem Cells Manufactured (Non-Industry Players)
  • Table 4.10. Stem Cell Therapies: In-House Manufacturers
  • Table 5.1. Stem Cell Therapy Manufacturing: Regulatory Authorities
  • Table 5.2. Stem Cell Therapies: Regulatory Considerations
  • Table 6.1. Stem Cell CMOs in North America: List of Profiled Companies
  • Table 6.2. FUJIFILM Cellular Dynamics: Company Overview
  • Table 6.3. FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
  • Table 6.4. GenCure: Company Overview
  • Table 6.5. GenCure: Overview of Manufacturing Capabilities
  • Table 6.6. PCT: Company Overview
  • Table 6.7. PCT: Overview of Manufacturing Capabilities
  • Table 6.8. Waisman Biomanufacturing: Company Overview
  • Table 6.9. Waisman Biomanufacturing: Overview of Manufacturing Capabilities
  • Table 6.10. WuXi Advanced Therapies: Company Overview
  • Table 6.11. WuXi Advanced Therapies: Overview of Manufacturing Capabilities
  • Table 7.1. Stem Cell CMOs in Europe and Asia: List of Profiled Companies Table 7.2
  • Table 7.3. BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
  • Table 7.4. Cell and Gene Therapy Catapult: Company Overview
  • Table 7.5. Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
  • Table 7.6. Lonza: Company Overview
  • Table 7.7. Lonza: Overview of Manufacturing Capabilities
  • Table 7.8. RoslinCT: Company Overview
  • Table 7.9. RoslinCT: Overview of Manufacturing Capabilities
  • Table 7.10. MEDINET: Company Overview
  • Table 7.11. MEDINET: Overview of Manufacturing Capabilities
  • Table 7.12. Nikon CeLL innovation: Company Overview
  • Table 7.13. Nikon CeLL innovation: Overview of Manufacturing Capabilities
  • Table 8.1. Stem Cell Therapy Contract Manufacturing Market: Partnerships and Collaborations, 2015-2019
  • Table 9.1. Supply Opportunity Assessment: List of Stem Cell Therapies Developers
  • Table 10.1. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Clean Rooms: Distribution by Size of Manufacturers (Sample Data Set for Industry Players)
  • Table 10.2. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Clean Rooms: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
  • Table 14.3. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Clean Rooms (Industry): Distribution by Size of Manufacturers
  • Table 10.4. Stem Cell Therapy Installed Manufacturing Capacity in Terms of Area of Clean Rooms (Industry): Distribution by Size of Manufacturers
  • Table 10.5. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Clean Rooms (Non-Industry): Average Capacity
  • Table 10.6 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Clean Rooms (Non-Industry): Average Capacity.
  • Table 11.1. Demand Analysis: List of Approved Stem Cell Therapies
  • Table 16.1. Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
  • Table 16.2. Stem Cell Therapy CMOs (Industry): Distribution by Company Size
  • Table 16.3. Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
  • Table 16.4. Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facility
  • Table 16.5. Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
  • Table 16.6. Stem Cell Therapy CMOs (Industry): Distribution by Scale of Operation
  • Table 16.7. Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cells
  • Table 16.8. Stem Cell Therapy CMOs (Industry): Distribution by Types of Stem Cells
  • Table 16.9. Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
  • Table 16.10. Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters
  • Table 16.11. Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Manufacturing Facility
  • Table 16.12. Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Services Offered
  • Table 16.13. Stem Cell Therapy CMOs: Distribution by Scale of Operation
  • Table 16.14. Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cells
  • Table 16.15. Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Stem Cells
  • Table 16.16. Stem Cell CMOs: Distribution of Manufacturing Facilities by Regulatory Authorities
  • Table 16.17. FUJIFILM Cellular Dynamics: Annual Revenues, 2014- Q1 2019 (USD Million)
  • Table 16.18. Hitachi: Annual Revenues, 2015- Q1 2019 (YEN Billion)
  • Table 16.19. WuXi Advanced Therapies: Annual Revenues, 2015- 2018 (RMB Million)
  • Table 16.20. Lonza: Annual Revenues, 2012- 2018 (CHF Million)
  • Table 16.21. Nikon CeLL innovation: Annual Revenues, 2015- 2018 (YEN Million)
  • Table 16.22. Partnerships and Collaborations: Cumulative Trend by Year, 2015-2019
  • Table 16.23. Partnerships and Collaborations: Distribution by Type of Agreement
  • Table 16.24. Partnerships and Collaborations: Trend by Type of Agreement and Year (2015-2019)
  • Table 16.25. Partnerships and Collaborations: Distribution by Types of Stem Cells
  • Table 16.26. Partnerships and Collaborations: Distribution by Scale of Operation and Type of Agreement
  • Table 16.27. Most Active Players: Analysis by Number of Partnerships
  • Table 16.28. Partnerships and Collaborations: Regional Distribution
  • Table 16.29. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 16.30. Stem Cell Therapy CMOs in North America: Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
  • Table 16.31. Stem Cell Therapy CMOs in North America: Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
  • Table 16.32. Stem Cell Therapy CMOs in North America: Contract Manufacturing Opportunity Assessment for Commercial Stage Molecules
  • Table 16.33. Stem Cell Therapy CMOs in Europe: Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
  • Table 16.34. Stem Cell Therapy CMOs in Europe: Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
  • Table 16.35. Stem Cell Therapy CMOs in Europe: Contract Manufacturing Opportunity Assessment for Commercial Stage Molecules
  • Table 16.36. Stem Cell Therapy CMOs in Asia Pacific: Contract Manufacturing Opportunity Assessment for Preclinical Stage Molecules
  • Table 16.37. Stem Cell Therapy CMOs in Asia Pacific: Contract Manufacturing Opportunity Assessment for Clinical Stage Molecules
  • Table 16.38. Stem Cell Therapy CMOs in Asia Pacific: Contract Manufacturing Opportunity Assessment for Commercial Stage Molecules
  • Table 16.39. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
  • Table 16.40. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
  • Table 16.41. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
  • Table 16.42. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
  • Table 16.43. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facilities
  • Table 16.44. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Range of Installed Capacity
  • Table 16.45. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
  • Table 16.46. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
  • Table 16.47. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facilities
  • Table 16.48. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
  • Table 16.49. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
  • Table 16.50. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facilities
  • Table 16.51. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Range of Installed Capacity
  • Table 16.52. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
  • Table 16.53. Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facilities
  • Table 16.54. Global Clinical Demand for Stem Cell Therapies
  • Table 16.55. Clinical Demand for Stem Cell Therapies: Distribution by Types of Stem Cells
  • Table 16.56. Clinical Demand for Stem Cell Therapies: Distribution by Source of Stem Cells
  • Table 16.57. Clinical Demand for Stem Cell Therapies: Distribution by Geographical Location
  • Table 16.58. Global Commercial Demand for Stem Cell Therapies
  • Table 16.59. Commercial Demand for Stem Cell Therapies: Distribution by Types of Stem Cells
  • Table 16.60. Commercial Demand for Stem Cell Therapies: Distribution by Source of Stem Cells
  • Table 16.61. Demand and Supply Distribution
  • Table 16.62. Overall Stem Cell Therapy Contract Manufacturing Market, 2019-2030 (USD Million)
  • Table 16.63. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells (USD Million)
  • Table 16.64. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells (USD Million)
  • Table 16.65. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
  • Table 16.66. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size (USD Million)
  • Table 16.67. Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
  • Table 16.68. Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030 (USD Million)
  • Table 16.69. Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.70. Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.71. Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.72. Stem Cell Therapy Contract Manufacturing Market in North America for Allogeneic Stem Cell Therapies, 2019-2030 (USD Million)
  • Table 16.73. Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
  • Table 16.74. Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
  • Table 16.75. Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
  • Table 16.76. Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
  • Table 16.77. Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
  • Table 16.78. Stem Cell Therapy Contract Manufacturing Market in North America For Large Companies, 2019-2030 (USD Million)
  • Table 16.79. Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
  • Table 16.80. Stem Cell Therapy Contract Manufacturing Market in Italy, 2019-2030 (USD Million)
  • Table 16.81. Stem Cell Therapy Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
  • Table 16.82. Stem Cell Therapy Contract Manufacturing Market in France, 2019-2030 (USD Million)
  • Table 16.83. Stem Cell Therapy Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
  • Table 16.84. Stem Cell Therapy Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
  • Table 16.85. Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.86. Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.87. Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.88. Stem Cell Therapy Contract Manufacturing Market in Europe for Allogeneic Stem Cell Therapies, 2019-2030 (USD Million)
  • Table 16.89. Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
  • Table 16.90. Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
  • Table 16.91. Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
  • Table 16.92. Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
  • Table 16.93. Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
  • Table 16.94. Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030 (USD Million)
  • Table 16.95. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World, 2019-2030 (USD Million)
  • Table 16.96. Stem Cell Therapy Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
  • Table 16.97. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.98. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.99. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
  • Table 16.100. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
  • Table 16.101. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Autologous Stem Cell Therapies, 2019-2030 (USD Million)

List of Companies

The following companies and organizations have been mentioned in the report:

  • 1. 3P Biopharmaceuticals
  • 2. AbbVie
  • 3. Accellta
  • 4. Adaptimmune
  • 5. Advancecells
  • 6. Advanced Cell Technology
  • 7. Aegle Therapeutics
  • 8. Aelan Cell Technologies
  • 9. AGC
  • 10. Ajinomoto
  • 11. Ajinomoto Kohjin Bio
  • 12. AllCells
  • 13. Allele Biotechnology & Pharmaceuticals
  • 14. Alpine BioTherapeutics
  • 15. American CryoStem
  • 16. Anagenesis Biotechnologies
  • 17. Andalusian Initiative for Advanced Therapies
  • 18. Angel Biotechnology
  • 19. Anterogen
  • 20. apceth Biopharma
  • 21. Aspire Health Science
  • 22. Astellas Pharma
  • 23. Asterias Biotherapeutics
  • 24. AstraZeneca
  • 25. Athersys
  • 26. Atlantic Bio GMP
  • 27. Avid Bioservices
  • 28. Axcelead Drug Discovery Partners
  • 29. Axiogenesis
  • 30. Baxter International
  • 31. Bellicum Pharmaceuticals
  • 32. Ben-Gurion University of the Negev
  • 33. Bio Elpida
  • 34. BioCardia
  • 35. Bioinova
  • 36. BioIVT
  • 37. BioLife Cell Bank
  • 38. Biological and Cellular GMP Manufacturing Facility, City of Hope
  • 39. BioNTech IMFS
  • 40. BioRestorative Therapies
  • 41. bluebird bio
  • 42. BlueRock Therapeutics
  • 43. Bone Therapeutics
  • 44. BrainStorm Cell Therapeutics
  • 45. Caladrius Biosciences
  • 46. Capicor Therapeutics
  • 47. CardioCell
  • 48. CardioCreate
  • 49. Case Western Reserve University School of Medicine
  • 50. Cell and Gene Therapy Catapult
  • 51. Cell Cure Neurosciences
  • 52. Cell Source
  • 53. Cell Tech Pharmed
  • 54. Cell Therapies
  • 55. Cell Therapy and Regenerative Medicine, University of Utah
  • 56. Cell Therapy Manufacturing Cooperative Research Centre
  • 57. Cellect Biotechnology
  • 58. Cellerant Therapeutics
  • 59. CELLforCURE
  • 60. CELLINK
  • 61. CellProthera
  • 62. Cells for Sight, Stem Cell Therapy Research Unit, University College London
  • 63. Cellular Biomedicine Group
  • 64. Cellular Therapy Core, University of Texas
  • 65. Celther Polska
  • 66. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  • 67. Center for Cell and Gene Therapy, Baylor College of Medicine
  • 68. Center for Molecular Medicine Cologne
  • 69. Center for Specialised Care & Research
  • 70. Centre for Cell and Vector Production (CCVP)
  • 71. Centre of Excellence for Cellular Therapy
  • 72. Chiesi Farmaceutici
  • 73. Clean Cells
  • 74. ClinImmune Labs
  • 75. CMC Biologics
  • 76. Cognate BioServices
  • 77. Colorado Center for Reproductive Medicine (CCRM)
  • 78. Cook MyoSite
  • 79. Corestem
  • 80. Creative Medical Technology Holdings
  • 81. Cryosite
  • 82. Cryoviva Biotech
  • 83. CSL Behring
  • 84. Cynata Therapeutics
  • 85. Cytopeutics
  • 86. Cytori Therapeutics
  • 87. Daiichi Sankyo
  • 88. Dendreon
  • 89. Digilab
  • 90. DiscGenics
  • 91. Duke University School of Medicine
  • 92. Eli Lilly
  • 93. Emory Personalized Immunotherapy Core
  • 94. ExCellThera
  • 95. Exopharm
  • 96. Fate Therapeutics
  • 97. Fibrocell
  • 98. Florey Institute of Neuroscience and Mental Health
  • 99. Fraunhofer Institute for Cell Therapy and Immunology
  • 100. FUJIFILM Cellular Dynamics
  • 101. FUJIFILM Irvine Scientific
  • 102. Gamida Cell
  • 103. Gates Biomanufacturing Facility
  • 104. GE Healthcare
  • 105. GenCure
  • 106. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • 107. Genxbio
  • 108. Genzyme Biosurgery
  • 109. Global Cell Med
  • 110. Global Stem Cells and Regenerative Medicine Acceleration Center
  • 111. Grace Century
  • 112. Guy's and St Thomas' Facility
  • 113. Gwo XI Stem Cell Applied Technology
  • 114. Harvard Stem Cell Institute, Harvard University
  • 115. Healios
  • 116. Helocyte
  • 117. HemoGenyx Pharmaceuticals
  • 118. Hemostemix
  • 119. Histocell
  • 120. Histogen
  • 121. Holostem Terapie Avanzate
  • 122. Ichor Therapeutics
  • 123. ID Pharma
  • 124. Institute of Liver & Biliary Sciences
  • 125. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  • 126. International Stem Cell Corporation
  • 127. iPS Academia Japan
  • 128. IQVIA Stem Cell Center
  • 129. Japan Tissue Engineering
  • 130. Japanese Society for Regenerative Medicine
  • 131. John Goldman Centre for Cellular Therapy
  • 132. Johnson & Johnson
  • 133. Kadimastem
  • 134. Kangstem Biotech
  • 135. KBI Biopharma
  • 136. Kohjin-Bio
  • 137. Kolon Life Sciences
  • 138. Kyoto University
  • 139. Kyushu University
  • 140. Laboratory for Cell and Gene Medicine, University of Stanford
  • 141. Life Stem Genetics
  • 142. Lifecells
  • 143. LifeSouth Community Blood Centers
  • 144. Living Cell Technologies
  • 145. Longeveron
  • 146. Lonza
  • 147. Magenta Therapeutics
  • 148. MaSTherCell
  • 149. Medeor Therapeutics
  • 150. MEDINET
  • 151. Medipost
  • 152. Merck
  • 153. Mesoblast
  • 154. Michael J Fox Foundation for Parkinson's Research
  • 155. Molecular and Cellular Therapeutics, University of Minnesota
  • 156. Moraga Biotechnology
  • 157. Morphogenesis
  • 158. Nanion Technologies
  • 159. National Eye Institute
  • 160. Nature Cell
  • 161. Neovii
  • 162. Nestlé Institute of Health Sciences
  • 163. Neuralstem
  • 164. NeuroGen Brain & Spine Institute
  • 165. NeuroGeneration
  • 166. New York Blood Center
  • 167. NHS Blood and Transplant (NHSBT)
  • 168. NIHR GOSH Biomedical Research Centre
  • 169. Nikon CeLL innovation
  • 170. Nohla Therapeutics
  • 171. Novadip Biosciences
  • 172. Novartis
  • 173. Ocata Therapeutics
  • 174. Octane Biotech
  • 175. OhioHealth
  • 176. OiDE BetaRevive
  • 177. Orchard Therapeutics
  • 178. Organogenesis
  • 179. Orgenesis
  • 180. Orisis Therapeutics
  • 181. Personalized Stem Cells
  • 182. Pfizer
  • 183. PharmaCell
  • 184. Pharmicell
  • 185. Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • 186. Pluristem Therapeutics
  • 187. Progenitor Cell Therapy (PCT)
  • 188. Promethera Biosciences
  • 189. Protide Pharmaceuticals
  • 190. Provia Laboratories
  • 191. Rayne Cell Therapy Suite, King's College London
  • 192. Regeneris Medical
  • 193. Regeneus
  • 194. ReNeuron
  • 195. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • 196. RHEACELL
  • 197. Roche
  • 198. ROHTO Pharmaceutical
  • 199. RoosterBio
  • 200. RoslinCT
  • 201. Roswell Park Cancer Institute
  • 202. Royal Free Hospital
  • 203. Samsung BioLogics
  • 204. SanBio
  • 205. Saneron CCEL Therapeutics
  • 206. Sangamo Therapeutics
  • 207. S-Biomedic
  • 208. Sclnow Biotechnology
  • 209. SCM Lifescience
  • 210. Scottish National Blood Transfusion Service (SNBTS)
  • 211. Sentien Biotechnologies
  • 212. SeouLin Bioscience
  • 213. Shanghai Biotechnology
  • 214. Sistemic
  • 215. SSM Health Cardinal Glennon Children's Hospital
  • 216. Stem Cell Theranostics
  • 217. Stem Cells Arabia
  • 218. StemBioSys
  • 219. STEMCELL Technologies
  • 220. Stemedica Cell Technologies
  • 221. StemGenn Therapeutics
  • 222. Steminent Biotherapeutics
  • 223. Stemline Therapeutics
  • 224. Stemmatters
  • 225. StemoniX
  • 226. Stempeutics Research
  • 227. Taiga Biotechnologies
  • 228. Taiwan Bio Therapeutics
  • 229. Takara Bio
  • 230. Takeda Pharmaceutical
  • 231. Terumo
  • 232. Theracell
  • 233. Tianhe Stem Cell Biotechnologies
  • 234. Tianjin Ever Union Biotechnology
  • 235. TiGenix
  • 236. Tissue Genesis
  • 237. TreeFrog Therapeutics
  • 238. U.S. Stem Cell
  • 239. UC Davis GMP Laboratory
  • 240. UC Irvine Medical Center
  • 241. UCI Beall Applied Innovation
  • 242. Universal Cells
  • 243. University Hospitals Case Medical Center
  • 244. University of California
  • 245. University of Manchester
  • 246. University of Newcastle
  • 247. Upstate Stem Cell cGMP Facility, University of Rochester
  • 248. Vecura, Karolinska University Hospital
  • 249. Vericel
  • 250. ViaCyte
  • 251. Viscofan
  • 252. Viscofan BioEngineering
  • 253. Vor Biopharma
  • 254. Waisman Biomanufacturing
  • 255. Worldwide Clinical Trials
  • 256. WuXi Advanced Therapies
  • 257. Xcelthera
  • 258. Xellbiogene
  • 259. YposKesi
Back to Top